| Heather L Robinson, SLP | |
|
4696 W Overland Rd Ste 228, Boise, ID 83705-2864 | |
| (208) 500-1728 | |
| Not Available |
| Full Name | Heather L Robinson |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 32 Years |
| Location | 4696 W Overland Rd Ste 228, Boise, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417175589 | NPI | - | NPPES |
| IDTPID015350 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP-1070 (Idaho) | Primary |
| Provider Name | Idaho Face & Voice Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356965941 PECOS PAC ID: 2466875877 Enrollment ID: O20200701002712 |
News Archive
Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.
For the first time researchers have studied the kind of physical pain that troubles adolescents with different mental health problems.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it completed the acquisition of the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. for a total cash consideration of RMB 435 million (approximately US$ 70.2 million) pursuant to the terms of the definitive agreement entered into on July 7, 2015.
Nearly 2 million adults in California, about 8 percent of the population, need mental health treatment, but the majority receive no services or inadequate services, despite a state law mandating that health insurance providers include mental health treatment in their coverage options, a new report by the UCLA Center for Health Policy Research shows.
Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather L Robinson, SLP 4696 W Overland Rd Ste 228, Boise, ID 83705-2864 Ph: (208) 500-1728 | Heather L Robinson, SLP 4696 W Overland Rd Ste 228, Boise, ID 83705-2864 Ph: (208) 500-1728 |
News Archive
Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.
For the first time researchers have studied the kind of physical pain that troubles adolescents with different mental health problems.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it completed the acquisition of the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. for a total cash consideration of RMB 435 million (approximately US$ 70.2 million) pursuant to the terms of the definitive agreement entered into on July 7, 2015.
Nearly 2 million adults in California, about 8 percent of the population, need mental health treatment, but the majority receive no services or inadequate services, despite a state law mandating that health insurance providers include mental health treatment in their coverage options, a new report by the UCLA Center for Health Policy Research shows.
Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).
› Verified 4 days ago
Jennifer Dahms, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2995 N Cole Rd, Suite 130, Boise, ID 83704 Phone: 208-559-2348 Fax: 888-559-4660 | |
Lauren Rose Addison, M.S. SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8620 W Emerald St Ste 100, Boise, ID 83704 Phone: 208-898-1368 | |
Kelli Shaw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3115 N Sycamore Dr, Boise, ID 83703 Phone: 208-401-6401 | |
Christy Baltazor, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Megan Patrick, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Emily Chapman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8860 W Evening Star Ln, Boise, ID 83709 Phone: 814-873-9144 | |
Kimberly Degraw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 N Curtis Rd Ste 204, Boise, ID 83706 Phone: 208-367-8282 |